CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 11 enrolled
Drug / intervention
Erlotinibdrug
Likely dose
Erlotinib 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01174043
NCT01174043Phase 2Completed
CompareCT.gov

Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia

Indiana University·interventional·Posted Aug 3, 2010·Updated Oct 13, 2023

In Brief

A Phase 2 clinical trial evaluating Erlotinib for Leukemia, Myelomonocytic, Acute. Completed, enrolled 11 participants across 1 site.

Detailed Summary

This research study is looking for patients with newly diagnosed acute myeloid leukemia (AML), AML that has returned (relapsed), or it has not responded adequately to previous treatments. Treating certain patients with chemotherapy may not be to their benefit or may cause more harm than benefit. The purpose of this study is to find out what effects (good and bad) erlotinib has on patients and their AML.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia, Myelomonocytic, Acute
CountriesUnited States
CollaboratorsOSI Pharmaceuticals

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedAug 3, 2010
Enrollment StartJul 1, 2010
Primary CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 15.9 years ago

Interventions

Erlotinibdrug

Erlotinib will be administered orally at 150 mg once a day, continuously. Each cycle will be 28 days and there will be no break between the cycles.